Core Insights - Deep Longevity, Inc is set to expand into the U.S. market in Q1 2026, targeting the rapidly growing health market valued at over $6.8 trillion [1][2] - The company offers clinically validated aging clocks that provide multi-dimensional biological age assessments, surpassing chronological age [1] - Deep Longevity aims to establish a local sales team in the U.S. to drive partnerships with various health-related entities [2] Group 1 - Deep Longevity's expansion into the U.S. is a significant milestone, with plans to capture a share of the $6.8 trillion health market [1][2] - The aging clocks developed by Deep Longevity include BloodAge, MindAge, BiometricAge, EpigeneticAge, and the upcoming FaceAge, providing personalized insights for consumers and healthcare providers [1][2] - The company has received support from numerous peer-reviewed papers and patents for its technology, which integrates various biological and psychological factors [2][3] Group 2 - The initial sales focus will be on the Southeastern U.S., including states like Alabama, Florida, and Georgia, with plans to build high-impact partnerships [2] - Deep Longevity's technology offers a vertical software as a service (SaaS) solution that provides personalized recommendations to improve health and extend healthy lifespan [3]

Core Insights - Deep Longevity, Inc. is set to expand into the U.S. market in Q1 2026, targeting the rapidly growing health market valued at over $6.8 trillion [1][2] - The company offers clinically validated aging clocks that provide multi-dimensional biological age assessments, surpassing chronological age [1][2] - Deep Longevity aims to establish partnerships with various health-related entities to enhance the distribution of its aging solutions [2] Company Expansion - Deep Longevity is forming a local sales team in the U.S., with the first two sales personnel starting on January 1, 2026 [2] - The initial focus of the sales team will be on the Southeastern U.S. states, including Alabama, Arkansas, Florida, Georgia, Kentucky, Louisiana, Mississippi, North Carolina, South Carolina, Tennessee, Virginia, and West Virginia [2] - The CEO of Deep Longevity emphasized the significance of entering the U.S. market as a milestone for the company [2] Technology and Offerings - The company’s aging clocks integrate various biological markers and psychological factors to provide comprehensive biological aging profiles [2][3] - Deep Longevity's technology is supported by numerous peer-reviewed papers and patents, enhancing its credibility in the market [2] - The company offers vertical software-as-a-service (SaaS) solutions that provide personalized recommendations to improve health and extend healthy lifespan [3]

Core Viewpoint - Deep Longevity, Inc. plans to expand into the U.S. market in Q1 2026, targeting the rapidly growing health market valued at over $6.8 trillion [1][2]. Group 1: Expansion Plans - Deep Longevity will establish a local sales team in the U.S., with the first two sales personnel joining on January 1, 2026 [2]. - The initial focus of the sales team will be on the Southeastern U.S. states, including Alabama, Arkansas, Florida, Georgia, Kentucky, Louisiana, Mississippi, North Carolina, South Carolina, Tennessee, Virginia, and West Virginia [2]. Group 2: Product Offerings - The company offers clinically validated aging clocks, including BloodAge, MindAge, BiometricAge, EpigeneticAge, and the upcoming FaceAge, which provide multi-dimensional biological age assessments beyond chronological age [1][2]. - Deep Longevity's technology is supported by numerous peer-reviewed papers and patents, integrating blood biomarkers, epigenetics, psychology, and biology to deliver comprehensive biological aging profiles [2]. Group 3: Business Model - Deep Longevity provides vertical software-as-a-service (SaaS) solutions that offer personalized recommendations to improve health and extend healthy lifespan [3].

二、中国太平洋财产保险股份有限公司浙江分公司应按照有关规定及时办理变更及许可证换领事宜。 2025年11月28日，国家金融监督管理总局衢州监管分局发布批复称，《中国太平洋财产保险股份有限公 司浙江分公司关于变更中国太平洋财产保险股份有限公司江山支公司营业场所的请示》（浙太保产 〔2025〕106号）收悉。经审核，现批复如下： 一、同意中国太平洋财产保险股份有限公司江山支公司的营业场所变更为：浙江省衢州市江山市双塔街 道锦绣大道99幢3号楼503-7室。 ...

Core Viewpoint - The global dry bulk shipping market is experiencing a rapid upturn, with the Baltic Dry Index (BDI) reaching its highest level since December 2023, indicating a positive trend for the industry [1] Group 1: Company Performance - Pacific Basin Shipping (02343) has seen its stock price increase by over 4%, currently trading at HKD 2.71 with a trading volume of HKD 32.43 million [1] Group 2: Industry Outlook - The dry bulk shipping industry is at a turning point, with moderate supply growth and three key demand catalysts expected to drive upward momentum: 1. The commencement of the West Simandou iron ore project, which is set to reshape the iron ore trade landscape 2. The Federal Reserve's interest rate cuts, which are favorable for commodity trading and dry bulk shipping 3. Long-term infrastructure needs, including post-war reconstruction in Ukraine and hydropower projects in Asia, contributing to marginal demand [1]

Core Viewpoint - The global dry bulk shipping market is experiencing a rapid upturn, with significant increases in the Baltic Dry Index (BDI) indicating a positive trend for the industry moving into 2025 [1] Group 1: Company Performance - Pacific Basin Shipping (02343) has seen its stock price rise by over 4%, currently trading at 2.71 HKD with a transaction volume of 32.43 million HKD [1] Group 2: Industry Outlook - The Baltic Dry Index has recorded 12 consecutive increases, reaching 2,560 points as of November 28, marking the highest level since December 2023 [1] - Long-term demand factors are expected to provide upward momentum for the dry bulk shipping industry, including the commencement of the West Simandou iron ore project, potential interest rate cuts by the Federal Reserve, and ongoing infrastructure needs related to post-war reconstruction in Ukraine and hydropower projects [1]

太平洋证券发布研报称，首次覆盖，给予康诺亚-B(02162)"买入"评级，目标股价82.07港元，中国特应 性皮炎药物市场正迎来高速增长期，以度普利尤单抗和司普奇拜单抗为代表的核心产品加速放量。同 时，康诺亚核心产品快速放量，重点管线进度领先，以及自免双抗CM512初步数据积极。 太平洋证券主要观点如下： 中国特应性皮炎药物市场将迅速增长 赛诺菲的度普利尤单抗(达必妥)已在美国、欧盟、日本及中国获批准上市，用于治疗儿童、青少年和成 人特应性皮炎，哮喘和慢性阻塞性肺疾病等，2024年全球销售额已达到141.4亿美元，为全球销售额第 四大药品。根据米内网数据显示，近年来该产品在中国市场迅速放量，2022年其销售额突破10亿元， 2023年以约48%的增速增长至超19亿元，2024年以约33%的增速增长至超25亿元。 (2)康悦达处于快速放量阶段，有望成为重磅大单品 根据康诺亚财报数据，司普奇拜单抗(康悦达)2024年实现销售收入约0.36亿元，2025年上半年实现销售 收入约1.70亿元，目前正处于快速放量阶段。随着过敏性疾病的医疗需求不断增长，司普奇拜单抗治疗 成人特应性皮炎、慢性鼻窦炎伴鼻息肉和季节性过敏性鼻 ...

太平洋证券发布研报称，首次覆盖，给予康诺亚-B(02162)"买入"评级，目标股价82.07港元，中国特应 性皮炎药物市场正迎来高速增长期，以度普利尤单抗和司普奇拜单抗为代表的核心产品加速放量。同 时，康诺亚核心产品快速放量，重点管线进度领先，以及自免双抗CM512初步数据积极。 太平洋证券主要观点如下： (2)康悦达处于快速放量阶段，有望成为重磅大单品 根据康诺亚财报数据，司普奇拜单抗(康悦达)2024年实现销售收入约0.36亿元，2025年上半年实现销售 收入约1.70亿元，目前正处于快速放量阶段。随着过敏性疾病的医疗需求不断增长，司普奇拜单抗治疗 成人特应性皮炎、慢性鼻窦炎伴鼻息肉和季节性过敏性鼻炎等适应症未来纳入医保后有望加速放量。此 外，司普奇拜单抗治疗青少年中重度特应性皮炎、结节性痒疹、哮喘、慢性阻塞性肺病等适应症的不断 扩展，有望促进其未来将保持强劲增长。 (3)全球首款长效TSLP x IL-13双抗初步展现BIC潜力 CM512是康诺亚自主研发的全球首款IgG-like长效型TSLP x IL-13双阻断剂，可同时靶向TSLP和IL-13， 能够早期抑制炎症级联反应的启动，有效减少Th2细胞 ...

据美联社加拿大多伦多11月28日报道，加拿大总理马克·卡尼和该国石油资源丰富的艾伯塔省的省长27 日达成谅解备忘录，将致力于建设一条通往太平洋沿海地区的石油管道，以使该国的石油出口目的地不 局限于美国、实现多样化。（参考消息） ...

Core Viewpoint - The recent political debate in Japan, particularly involving Prime Minister Kishi Sanae's comments on Taiwan, has raised significant concerns about Japan's political direction and its implications for Sino-Japanese relations [2][4][19]. Group 1: Political Context - Kishi Sanae's remarks regarding Taiwan being a "crisis for Japan's survival" have led to a deterioration in Sino-Japanese relations, prompting questions about her accountability for this shift [4][6]. - The debate highlighted a strategic ambiguity in Japan's political stance on Taiwan, with Kishi avoiding references to established political agreements between China and Japan [2][10]. - The opposition party, led by Noda Yoshihiko, has criticized Kishi's statements, indicating a potential political maneuvering rather than a straightforward confrontation [10][12]. Group 2: Reactions and Implications - Kishi did not retract her controversial statements but suggested they were spontaneous responses to specific situations, which has led to further speculation about her intentions [8][21]. - The use of the "San Francisco Peace Treaty" in her arguments has been deemed illegal and invalid, raising concerns about Japan's adherence to international agreements regarding Taiwan [23][25]. - Analysts suggest that Kishi's actions reflect a broader trend of rightward political shifts in Japan, with implications for national security and military policy [30][41]. Group 3: Military and Security Policy - Kishi's administration is pushing for an increase in defense spending and a revision of Japan's pacifist constitution, indicating a significant shift in Japan's military posture [35][41]. - The recent political developments have emboldened pro-independence sentiments in Taiwan, leading to increased military budgets and preparations in response to perceived threats from China [37][39]. - The Japanese government's recent decisions signal a departure from previous commitments to maintain a peaceful stance, raising alarms about a potential resurgence of militarism in Japan [45][50].